Abbott's drug-coated stent was announced to be superior over Boston Scientific's Taxus stent at treating clogged heart arteries which caused share prices to jump from USD $53.86 to USD $57.24.
Abbott's release of new DNA tests in Europe to detect chromosomal abnormalities associated with some forms of leukemia send share price on an upward trend until January 24, when Abbott announces their 4th Quarter loss on the Kos Deal.
Abbott's share price fell from USD $47.47 to USD $45.65 after Abbott announced the acquisition of Kos Pharamaceuticals, Inc. for $3.7 billion.